Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio, Integra Biosciences, Ambion

Premium

Cisbio has released the IP-One Assay System, an assay development tool based on the company's HTRF technology platform. The company said that the IP-One is the first high-throughput system that can easily detect inositol(1)phosphate, which is one of the major products of the phosphatidyl inositol cascade and tightly correlates with Gq-coupled activity.


Integra Biosciences has released the CELLspin, a compact system with remote control for spinning cell culture volumes from 100 ml to 1000 ml at 5 rpm to 75 rpm. Two CELLspin systems fit comfortably inside a standard size incubator, the company said.


Ambion has introduced its Pre-miR miRNA precursor molecules, which are chemically modified and optimized nucleic acids designed to mimic the microRNA molecules in cells, the company said. They are designed to directly enter into the miRNA processing pathway, and "are treated identically to endogenous miRNA within the cell. Since the … molecules directly enter the miRNA pathway, they eliminate any non-miRNA cellular response that is seen with siRNA-like designs." Additional details about the molecules can be found at http://www.ambion.com/catalog/CatNum.php?17110.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.